Statement: the primary trial cohorts are not seperated based on patient characteristics.
Primary_evidence: INTERVENTION 1:    Monotherapy: Alobresib 0.6 mg   Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy, or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD. INTERVENTION 2:    Monotherapy: Alobresib 1.4 mg   Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy, or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD.